Small-cell lung cancer (SCLC) is the most lethal type of lung cancer, characterized by rapid evolution from chemosensitivity to chemoresistance and limited treatment options. However, the mechanisms underlying this evolution remain poorly understood. Here, we show that Retinoid X receptor γ (RXRγ) is uniquely overexpressed in chemo-resistant SCLC tumors, and that RXRγ serves as an essential factor driving chemoresistance in SCLC. RXRγ forms phase-separated droplets with LSD1 in the nucleus, which enhances RXRγ-mediated gene transcription activity and reprograms gene expression, promoting tumor stemness and metastasis, and eventually driving SCLC chemoresistance. In turn, RXRγ antagonist disrupts RXRγ–LSD1 interaction, reducing their binding to the target gene locus, markedly suppressing the expression of the RXRγ target gene network. Finally, RXRγ antagonists strongly suppress tumor growth and metastasis and restore SCLC vulnerability to chemotherapy in multiple preclinical SCLC models, resulting in a substantial extension of survival in mouse models. Thus, these results establish RXRγ as a key player in SCLC by phase separation and as a potential therapeutic target for this deadly disease.
Breast cancer remains a global health challenge with varied prognoses despite treatment advancements. Therefore, this study explores the pseudogene MGAT4EP as a potential biomarker and therapeutic target in breast cancer. Using TCGA data and bioinformatics, MGAT4EP was identified as significantly overexpressed in breast cancer tissues and associated with poor prognosis. Multivariate Cox regression confirmed MGAT4EP as important prognostic factor. A clinical prediction model based on MGAT4EP expression showed high accuracy for 1-, 3-, and 5-year survival rates and was translated into a nomogram for clinical application. Functional studies revealed that silencing MGAT4EP via siRNA promoted apoptosis, inhibited migration and invasion in breast cancer cells. RNA-seq, GSEA, and GO analyses linked MGAT4EP to apoptosis and focal adhesion pathways. Notably, knock down of MGAT4EP significantly suppressed tumor growth and metastasis in xenograft and lung metastasis models. Taken together, these findings establish MGAT4EP as an attractive target for metastatic breast cancer and provide a potential a promising therapeutic target for breast cancer treatment.
26 May 2026 in Biochemical and Biophysical Research Communications
Figure S5. Interaction between DNA binding domains of HIF-1α and RORγ prevents HIF-1α hydroxylation and promotes its nuclear translocation, related to Fig.5.
Peritoneal metastasis (PM) is the most common and lethal form of metastasis in gastric cancer, highlighting an urgent need for treatment strategies. In this study, we identified retinoic acid receptor–related orphan receptor gamma (RORγ) as a key driver of PM in gastric cancer tumors. Integrative bioinformatics and IHC analyses revealed aberrant upregulation of RORγ in gastric cancer tumors, particularly in metastatic lesions. Functionally, elevated RORγ promoted gastric cancer cell adaptation to hypoxia and accelerated PM formation in vivo. The hypoxic microenvironment in gastric cancer stimulated RORγ expression, which in turn enhanced hypoxia-inducible factor 1α (HIF1α) stability, establishing a positive feedforward loop. Mechanistically, RORγ interacted with HIF1α and protected it from binding to proline hydroxylase domain 3 and von Hippel-Lindau, resulting in markedly decreased HIF1α hydroxylation and ubiquitylation and increased HIF1α accumulation, nuclear translocation, and transactivation. The RORγ–HIF1α complex bound to and activated target genes involved in the hypoxic response and epithelial-to-mesenchymal transition, thereby driving gastric cancer tumor growth and PM. Disruption of the RORγ–HIF1α interaction using RORγ antagonists markedly promoted HIF1α degradation and diminished its function. Importantly, in multiple gastric cancer xenograft models, RORγ inhibition effectively blocked tumor growth and PM while sensitizing tumors to chemotherapy. Thus, this study uncovers a mechanism of hypoxia-mediated metastasis through a RORγ–HIF1α reciprocal regulatory loop and offers a potential therapeutic option against PM in advanced cancer.Significance:RORγ drives peritoneal metastasis in gastric cancer and can be targeted to block metastatic progression, suggesting that RORγ inhibition could serve as a therapeutic strategy for advanced gastric cancer.